Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of relevance. This is page number 5.
Order by Relevance | Date
Total 36235 results found since Jan 2013.
Education Aimed at Patient Safety Management of Chemotherapy Conducted at University Education Sites
Yakugaku Zasshi. 2023;143(3):213-216. doi: 10.1248/yakushi.22-00160-1.ABSTRACTThe School Education Law was revised in 2006, and the university pharmacy education system and the national pharmacist examination system were changed. In line with the advancement of medical technology and the division of labor, 16 years have passed since the length of undergraduate pharmacy education was extended from 4 to 6 years in order to foster highly qualified pharmacists. During this period, the curriculum for practical training has been revised, and lectures and exercises focused on clinical education have been incorporated to foster ph...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - March 1, 2023 Category: Drugs & Pharmacology Authors: Kenichi Suzuki Source Type: research
Survey: Most Oncologists Discuss Medical Marijuana with Cancer Patients
Medical marijuana continues to be a hot topic among mesothelioma patients and a popular way to cope with disease symptoms and treatment side effects.
As more states legalize marijuana for medicinal purposes, more cancer patients are asking their doctors about the natural therapy. A recent survey published in the Journal of Clinical Oncology shows as many as 80 percent of oncologists talk about medical marijuana with their patients.
Of the 237 oncologists who responded to the survey, more than half (55 percent) practice in one of the 28 states where medical marijuana is legal.
Questions on the survey covered recommendations...
Source: Asbestos and Mesothelioma News - June 1, 2018 Category: Environmental Health Authors: Daniel King Source Type: news
Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer.
CONCLUSION: Within the limitations of this single-center retrospective analysis, clinically stable patients who were judged by clinicians to be eligible for continuing ICIs treatment post-DR derived apparent OS benefit than discontinuing counterpart.
PMID: 32518972 [PubMed - indexed for MEDLINE]
Source: Clinical Lung Cancer - October 8, 2020 Category: Cancer & Oncology Authors: Zhou H, Sun Y, Xiu W, Han J, Zhong L, Suo J, Wei H, Wang Y, Zhu J Tags: J Cancer Res Clin Oncol Source Type: research
Oral Immunotherapy for Multiple Foods in a Pediatric Allergy Clinic Setting.
CONCLUSION: A similar approach to that used for peanut OIT can be taken for non-peanut foods, and for multiple foods simultaneously. High baseline allergy test results are not a contraindication to OIT.
PMID: 31494236 [PubMed - as supplied by publisher]
Source: Annals of Allergy, Asthma and Immunology - September 4, 2019 Category: Allergy & Immunology Authors: Eapen AA, Lavery WJ, Siddiqui JS, Lierl MB, Cincinnati Children’s Hospital Medical Center, Division of Allergy and Immunology Tags: Ann Allergy Asthma Immunol Source Type: research
Stand up to cancer releases nurses training modules for new immuno-oncology therapies
(Entertainment Industry Foundation) Stand Up To Cancer (SU2C) released complimentary Continuing Nursing Education (CNE) training modules to equip nurses to manage the unique challenges and patient symptoms that accompany administration of emerging cancer immunotherapies. Focused on immunology and related pathophysiology, symptom management, and nursing interventions to reduce symptom distress and promote wellness, these modules meet CNE standards and each module provides 3.5 -- 5 contact hours from the Boston College William F. Connell School of Nursing.
Source: EurekAlert! - Cancer - May 4, 2017 Category: Cancer & Oncology Source Type: news
Feasibility and preliminary effectiveness of virtual reality as a patient education tool for people with cancer undergoing immunotherapy: a protocol for a randomised controlled pilot study in a regional setting
The objective of this randomised, single-centre pilot study is to examine the feasibility and preliminary effectiveness of VR as an education tool for people with cancer. The results will provide data to inform the feasibility of a future randomised controlled trial, including sample size calculations.
Methods and analysis
Patients with cancer undergoing immunotherapy will be recruited. A total of 36 patients will be recruited and randomised to one of three trial arms. Participants will be randomised 1:1:1 to receive VR, a two-dimensional video or standard care (ie, verbal communication and information leaflets). Feasibil...
Source: BMJ Open - June 13, 2023 Category: General Medicine Authors: van der Kruk, S. R., Gunn, K. M., MacDougall, H., Milne, D., Smith, K., Zielinski, R. Tags: Open access, Oncology Source Type: research
Targeting PD-1 Pathway; A new hope for Gastrointestinal Cancers.
CONCLUSION: Both pembrolizumab and nivolumab showed promising efficacy with acceptable safety data in GI cancers especially in refractory MSI positive metastatic colorectal cancer in the era of published trials.
PMID: 28055269 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - January 7, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Durvalumab Boots PFS Even in Stage 3 Lung Cancer Durvalumab Boots PFS Even in Stage 3 Lung Cancer
Immunotherapy is continuing its march: the first trial of an anti-PD-L1 inhibitor in stage 3 non-small cell lung cancer has shown an impressive increase in progression-free survival.Medscape Medical News
Source: Medscape Medical News Headlines - September 9, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost
Publication date: Available online 12 September 2019Source: Journal of the Formosan Medical AssociationAuthor(s): Chun-Nan Kuo, Yu-Ming Liao, Li-Na Kuo, Hui-Ju Tsai, Wei-Chiao Chang, Yun YenCancer is the leading cause of death in Taiwan, and the overall incidence rate has gradually increased. The four most common cancers in Taiwan are colorectal, lung, breast and liver cancers. With the rise in incidence, the clinical use and costs of all anticancer drugs have steadily increased. The costs of novel therapeutics, such as targeted therapies and immunotherapy were accounted almost two-third of all antineoplastic agents in Tai...
Source: Journal of the Formosan Medical Association - September 14, 2019 Category: General Medicine Source Type: research
The chemo ’s too much, but getting on a clinical trial is gruelling enough
Continuing his account of his illness, Steve Hewlett suffers a setback as he waits nervously for new drugsNow sharp-eyed readers may have spotted that this diary starts the day before the last one was published! By way of a little back story, my doctors have been trying to get me on to a clinical trial featuring new immunotherapy treatments, on the basis that my first line of chemotherapy worked well initially and then failed completely, and the second-line chemo, while it did show signs of working, was proving pretty hard for me to tolerate. But getting on to clinical trials has proved more than a trial in itself!Continue reading...
Source: Guardian Unlimited Science - January 22, 2017 Category: Science Authors: Steve Hewlett Tags: Cancer Health Society Cancer research Medical research Science Source Type: news
The evidence for biologic immunotherapy in Sarcoidosis: A systematic review
Conclusion There are insufficient data to suggest the long-term efficacy of anti-TNFα inhibitors in the treatment of sarcoidosis. This may be due to heterogeneity, small sample sizes and the lack of consistent reporting of outcome measures.
Source: Australasian Medical Journal - AMJ - October 4, 2017 Category: General Medicine Source Type: research
Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease.
CONCLUSION: Detecting changes in tau and targeting tau pathology represent a promising lead in the diagnosis and treatment of AD.
PMID: 29237931 [PubMed - in process]
Source: Chinese Medical Journal - December 15, 2017 Category: General Medicine Authors: Wu XL, Piña-Crespo J, Zhang YW, Chen XC, Xu HX Tags: Chin Med J (Engl) Source Type: research
A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
CONCLUSION: Long-term extrapolation of OS is required for NICE STAs based on initial immature OS data. The results of this study demonstrate that the initial OS extrapolations employed by manufacturers and ERGs generally predicted OS reasonably well when compared to more mature data (when available), though on average they appeared to underestimate OS. This review and validation shows that while the choice of OS extrapolation is uncertain, the methods adopted are generally aligned with later-published follow-up data and appear appropriate for informing HTA decisions.
PMID: 30422080 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - November 15, 2018 Category: Health Management Tags: J Med Econ Source Type: research
ASCO 2020 non-small lung cancer (NSCLC) personal highlights
SummaryIn this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering developments in early and advanced-stage NSCLC. Until recently early stage NSCLC patients were treated independently of their genetic profile. Now the ADAURA study proved that postoperative osimertinib significantly prolongs disease-free survival compared to standard chemotherapy in EGFR-mutated NSCLC , underlining the high efficacy of targeted therapies in early stages. In advanced-stage disease, of course immunotherapy (IO) was at the center of attention. Final analysis of KEYNOTE-189 ...
Source: Memo - Magazine of European Medical Oncology - January 13, 2021 Category: Cancer & Oncology Source Type: research
